Pennsylvania is currently home to 3312 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
NCT02323581
Recruiting
Prospective, nonrandomized, single-center, two-arm study to assess the feasibility and safety and to evaluate clinical outcomes of endovascular repair of complex aortic aneurysms (thoracoabdominal aortic aneurysms and aortic arch aneurysms) in patients at high risk for open surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal
Register for Updates
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768
Recruiting
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Non-small Cell Lung Cancer, Lung Cancer
Register for Updates
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
NCT06496243
Recruiting
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/12/2024
Locations: UPenn, Philadelphia, Pennsylvania
Conditions: Dyslipidemias
Register for Updates
Comparative Effectiveness of Online 8-session CBT Vs. 1-Session Empowered Relief for Chronic Pain - the PROGRESS Study
NCT05612750
Recruiting
The purpose of this study is to conduct a pragmatic clinical trial comparing the effectiveness of: (1) 8-week cognitive behavioral therapy for chronic pain (pain-CBT; sixteen hours total treatment time); and (2) a 1-session pain relief skills intervention for chronic pain (Empowered Relief; two hours total treatment time).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Lehigh Valley Health Network, Allentown, Pennsylvania
Conditions: Pain, Chronic, Lupus, Pelvic Pain
Register for Updates
Neurofeedback for Borderline Personality Disorder
NCT05398627
Recruiting
The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/12/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Borderline Personality Disorder
Register for Updates
The Impact of Oral Health in HIV Patients on Antiretroviral Therapy
NCT04645693
Recruiting
This is a prospective cohort study designed to investigate the range of metabolic abnormalities observed in patients living with HIV on antiretroviral therapy. This study will also explore the concurrent role of poor oral health in supporting and driving chronic immune activation and inflammation in HIV infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania
Conditions: HIV, Periodontal Diseases, Caries, Non-communicable Disease, Xerostomia
Register for Updates
Study in Parkinson Disease of Exercise
NCT04284436
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Parkinson Disease
Register for Updates
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Recruiting
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Register for Updates
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
NCT03266653
Recruiting
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Register for Updates
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NCT03266640
Recruiting
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cytomegalovirus Infections, Primary Immune Deficiency Disorder
Register for Updates
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
NCT03266627
Recruiting
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
11/12/2024
Locations: Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Adenovirus, Primary Immune Deficiency Disorder
Register for Updates
Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia
NCT02549820
Recruiting
CDH is a birth defect characterized by the development, very early in gestation, of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, the intestines and other organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally. In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/12/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Register for Updates